申请人:Eisai R&D Management Co., Ltd.
公开号:US20200347050A1
公开(公告)日:2020-11-05
Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.